# Dishman Carbogen Amcis (NSE: DCAL) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/DCAL · Pivot · prices to 22 Oct 2026

Dishman Carbogen Amcis (NSE: DCAL) closed at ₹141.95 on 22 Oct 2026, up 0.07% on the day. With a market capitalisation of ₹2,226 Cr, it ranks 1100th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Biotechnology.

At its last close the stock traded at 22.8× trailing earnings, against a return on equity of 1.5% in FY26. Over the past year the share price has fallen 49.1%. Its 52-week range is ₹128.50 (30 Mar 2026) to ₹303.00 (31 Oct 2025); the last close is 53.2% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹851 Cr (+18.9% year on year) and net profit ₹22 Cr (−49.5%), on a consolidated basis. Promoters held 59.32% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹141.95 |
| Market cap | ₹2,226 Cr |
| P/E (trailing) | 22.8 |
| ROE | 1.5% (FY26) |
| ROCE | 2.9% (FY26) |
| Debt to equity | 0.42 |
| 52-week high | ₹303.00 (31 Oct 2025) |
| 52-week low | ₹128.50 (30 Mar 2026) |
| 1-year return | −49.1% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹851 Cr | +18.9% | ₹22 Cr | −49.5% | ₹1.39 |
| Q3 FY26 | ₹720 Cr | +5.5% | −₹13 Cr | −380.1% | −₹0.83 |
| Q2 FY26 | ₹653 Cr | −17.3% | ₹65 Cr | +97.2% | ₹4.16 |
| Q1 FY26 | ₹708 Cr | +35.2% | ₹23 Cr | — | ₹1.49 |
| Q4 FY25 | ₹716 Cr | +9.4% | ₹43 Cr | — | ₹2.75 |
| Q3 FY25 | ₹682 Cr | +4.8% | ₹5 Cr | — | ₹0.30 |
| Q2 FY25 | ₹789 Cr | +34.5% | ₹33 Cr | — | ₹2.11 |
| Q1 FY25 | ₹524 Cr | −27.6% | −₹78 Cr | −556.3% | −₹4.95 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹2,712 Cr | ₹3 Cr |
| FY24 | ₹2,616 Cr | −₹153 Cr |
| FY23 | ₹2,413 Cr | −₹30 Cr |
| FY22 | ₹2,141 Cr | ₹18 Cr |
| FY21 | ₹1,912 Cr | −₹165 Cr |
| FY20 | ₹2,044 Cr | ₹159 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 59.32%
- Foreign institutions: 6.86%
- Domestic institutions: 2.07%
- Non-institutions: 31.75%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Alembic](https://app.pivotnow.in/stock/ALEMBICLTD) | ₹92.33 | ₹2,371 Cr | 7.5 | — |
| [Fredun Pharmace](https://app.pivotnow.in/stock/FREDUN) | ₹1,376.10 | ₹2,276 Cr | 22.5 | — |
| [Vimta Labs](https://app.pivotnow.in/stock/VIMTALABS) | ₹495.55 | ₹2,214 Cr | 28.5 | — |
| [Medi Assist Healthcare Services](https://app.pivotnow.in/stock/MEDIASSIST) | ₹291.75 | ₹2,179 Cr | 24.1 | — |
| [Syncom Formulations (India)](https://app.pivotnow.in/stock/SYNCOMF) | ₹22.83 | ₹2,146 Cr | 28.2 | — |
| [Indoco Remedies](https://app.pivotnow.in/stock/INDOCO) | ₹230.55 | ₹2,128 Cr | — | — |

## Questions and answers

### What is the share price of Dishman Carbogen Amcis today?

Dishman Carbogen Amcis (NSE: DCAL) last closed at ₹141.95 on 22 Oct 2026. Its 52-week high is ₹303.00 and its 52-week low is ₹128.50.

### What is the market cap of Dishman Carbogen Amcis?

Dishman Carbogen Amcis' market capitalisation is ₹2,226 Cr (₹2,226 Cr) at the 22 Oct 2026 close, ranking 1100th among the NSE companies Pivot tracks.

### What is the P/E ratio of Dishman Carbogen Amcis?

Dishman Carbogen Amcis trades at a trailing P/E of 22.8. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 24.1.

### What is the ROE and ROCE of Dishman Carbogen Amcis?

Return on equity was 1.5% in FY26 and return on capital employed was 2.9% in FY26 (consolidated figures).

### Is Dishman Carbogen Amcis a debt-free company?

No. Dishman Carbogen Amcis' debt-to-equity ratio was 0.42 in FY26, with total debt of ₹1,535 Cr.

### What were Dishman Carbogen Amcis' latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Dishman Carbogen Amcis reported revenue of ₹851 Cr, +18.9% year on year, and net profit of ₹22 Cr, −49.5% year on year.

### How has Dishman Carbogen Amcis stock performed over the last year?

Dishman Carbogen Amcis' share price has fallen 49.1% over the past year, −23.3% over three months and −17.0% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Dishman Carbogen Amcis?

As of 30 Jun 2026: promoters 59.32%, foreign institutions 6.86%, domestic institutions 2.07%, non-institutions 31.75%.

### Who are Dishman Carbogen Amcis' competitors?

The listed Pharma & Healthcare companies closest to Dishman Carbogen Amcis by market cap are Alembic, Fredun Pharmace, Vimta Labs, Medi Assist Healthcare Services, Syncom Formulations (India) and Indoco Remedies.

### Is Dishman Carbogen Amcis a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Dishman Carbogen Amcis' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on DCAL against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.